A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics of GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU Authorized Keytruda® in Participants With Stage II and III Melanoma Requiring Adjuvant Treatment With Pembrolizumab
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
AUDI ADAWIAH BT SULAIMAN SHAH
CONTACT
SC: Puteri Nur Najwa Nor Azman, Anis Amira Aznan
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
SUHANA BINTI YUSAK
CONTACT
SC: Shamiza binti Ahmad Shaharudin
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
Study title: A randomized, double-blind, parallel-group study to compare pharmacokinetics of GME751 (proposed pembrolizumab biosimilar) and US-licensed and EUauthorized Keytruda® in participants with stage II and III melanoma requiring adjuvant treatment with pembrolizumab (Jimmy Mel)
University Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr David Lee Dai Wee
CONTACT
SC: Toh Yok Yong
Contact: 03-79492120
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogeneticity of ABP 206 Compared with OPDIVO (Nivolumab) in Subjects with Treatment-Naive Unresectable or Metastatic Melanoma
Phase III, Line of therapy: 1st line
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Eng Jie Yi
CONTACT
SC: Erfan Salbi, Dafne Diana Gabriel
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
SUHANA BINTI YUSAK
CONTACT
SC: Siti Amirah Ishak, Shamiza Ahmad Shaharudin, Hidayati Mohd, Abdul Hadi, Anis Hazirah Asmali, Yong Xian Lerk, Erda Syerena Rosli
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
CHOONG SWEE HSIA
CONTACT
SC: Noor Aishah Robani, Yogabaanu A/P Ulaganathan
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
EZNAL IZWADI BIN MOHD MAHIDIN
CONTACT
SC: Anis Atifah Mohd Hisham , Nurshahida Binti Mohd Nawi, Puteri Nur Aliah Binti Wan Faizal
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
MASTURA BINTI MD YUSOF
CONTACT
SC: Melissa Lian Qianyue
General Line: 03 – 2296 0888
CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322
A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting
Resected Stage III or Stage IV Melanoma
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
EZNAL IZWADI BIN MOHD MAHIDIN
CONTACT
SC: Hanani, Puteri Nur Aliah
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
SUHANA BINTI YUSAK
CONTACT
SC: Shamiza, Hidayati, Erda Syerena
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
CHOONG SWEE HSIA
CONTACT
SC: Nur Adilah, Nurul Bisyarah Husna
General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Eng Jie Yi
CONTACT
SC: Dafne Diana Gabriel
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)